Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
METHODS: This is a real-world, multicenter, retrospective cohort within the United States between 2017 and 2020. Adult patients who received MEV for ≥72 hours were eligible for inclusion. The primary outcome was 30-day mortality. Classification and regression tree analysis (CART) was used to identify the time breakpoint (BP) that delineated the risk of negative clinical outcomes (NCOs) and was examined by multivariable logistic regression analysis (MLR).
RESULTS: Overall, 126 patients were evaluated from 13 medical centers in 10 states. The most common infection sources were respiratory tract (38.1%) and intra-abdominal (19.0%) origin, while the most common isolated pathogens were CRE (78.6%). Thirty-day mortality and recurrence occurred in 18.3% and 11.9%, respectively. Adverse events occurred in 4 patients: nephrotoxicity (n = 2), hepatoxicity (n = 1), and rash (n = 1). CART-BP between early and delayed treatment was 48 hours (P = .04). MEV initiation within 48 hours was independently associated with reduced NCO following analysis by MLR (adusted odds ratio, 0.277; 95% CI, 0.081-0.941).
CONCLUSIONS: Our results support current evidence establishing positive clinical and safety outcomes of MEV in GNIs, including CRE. We suggest that delaying appropriate therapy for CRE significantly increases the risk of NCOs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 8(2021), 8 vom: 25. Aug., Seite ofab371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alosaimy, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carbapenem-resistant Enterobacterales |
|---|
| Anmerkungen: |
Date Revised 26.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofab371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329738976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329738976 | ||
| 003 | DE-627 | ||
| 005 | 20231225205755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofab371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329738976 | ||
| 035 | |a (NLM)34430671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alosaimy, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE) | ||
| 520 | |a METHODS: This is a real-world, multicenter, retrospective cohort within the United States between 2017 and 2020. Adult patients who received MEV for ≥72 hours were eligible for inclusion. The primary outcome was 30-day mortality. Classification and regression tree analysis (CART) was used to identify the time breakpoint (BP) that delineated the risk of negative clinical outcomes (NCOs) and was examined by multivariable logistic regression analysis (MLR) | ||
| 520 | |a RESULTS: Overall, 126 patients were evaluated from 13 medical centers in 10 states. The most common infection sources were respiratory tract (38.1%) and intra-abdominal (19.0%) origin, while the most common isolated pathogens were CRE (78.6%). Thirty-day mortality and recurrence occurred in 18.3% and 11.9%, respectively. Adverse events occurred in 4 patients: nephrotoxicity (n = 2), hepatoxicity (n = 1), and rash (n = 1). CART-BP between early and delayed treatment was 48 hours (P = .04). MEV initiation within 48 hours was independently associated with reduced NCO following analysis by MLR (adusted odds ratio, 0.277; 95% CI, 0.081-0.941) | ||
| 520 | |a CONCLUSIONS: Our results support current evidence establishing positive clinical and safety outcomes of MEV in GNIs, including CRE. We suggest that delaying appropriate therapy for CRE significantly increases the risk of NCOs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a carbapenem-resistant Enterobacterales | |
| 650 | 4 | |a gram-negative infections | |
| 650 | 4 | |a meropenem-vaborbactam | |
| 650 | 4 | |a multidrug-resistant | |
| 700 | 1 | |a Lagnf, Abdalhamid M |e verfasserin |4 aut | |
| 700 | 1 | |a Morrisette, Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Scipione, Marco R |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jing J |e verfasserin |4 aut | |
| 700 | 1 | |a Jorgensen, Sarah C J |e verfasserin |4 aut | |
| 700 | 1 | |a Mynatt, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Carlson, Travis J |e verfasserin |4 aut | |
| 700 | 1 | |a Jo, Jinhee |e verfasserin |4 aut | |
| 700 | 1 | |a Garey, Kevin W |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, David |e verfasserin |4 aut | |
| 700 | 1 | |a DeRonde, Kailynn |e verfasserin |4 aut | |
| 700 | 1 | |a Vega, Ana D |e verfasserin |4 aut | |
| 700 | 1 | |a Abbo, Lilian M |e verfasserin |4 aut | |
| 700 | 1 | |a Venugopalan, Veena |e verfasserin |4 aut | |
| 700 | 1 | |a Athans, Vasilios |e verfasserin |4 aut | |
| 700 | 1 | |a Saw, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Claeys, Kimberly C |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Kyle C |e verfasserin |4 aut | |
| 700 | 1 | |a Veve, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kufel, Wesley D |e verfasserin |4 aut | |
| 700 | 1 | |a Amaya, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Yost, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Ortwine, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Rybak, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 8(2021), 8 vom: 25. Aug., Seite ofab371 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:8 |g day:25 |g month:08 |g pages:ofab371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofab371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 8 |b 25 |c 08 |h ofab371 | ||